TriangleHEALTH PROFESSIONAL · SOURCE READING
Ibrutinib
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia
Ibrutinib, a tyrosine kinase inhibitor, has been studied in the treatment of hairy cell leukemia.
Evidence (ibrutinib):
In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]
Source links and citations
In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]
The response rate was 54%.
In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]
The estimated 36-month PFS rate was 73%.
In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]
The OS rate was 85%.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice